Government Drug Pricing Forum Speakers

Christopher A. Hatwig, MS, RPh, FASHP


Apexus/340B Prime Vendor Program

Christopher A. Hatwig, MS, RPh is President of Apexus, an organization responsible for managing the Human Resources and Services Administration’s (HRSA) 340B Prime Vendor Program. Mr. Hatwig works closely with HRSA’s Office of Pharmacy Affairs and the Pharmacy Services Support Center in Washington, DC to educate all stakeholders, and to improve the integrity and value of the 340B Drug Pricing Program for the nation’s safety-net providers. Participants of the program include over 12,000 HRSA grantees and disproportionate share hospitals serving the nation’s low income and uninsured populations. The Prime Vendor provides added value by collectively representing the 340B covered entities’ purchases to secure federal sub-ceiling discounts on pharmaceuticals and discounts on other outpatient pharmacy related products and services.

Mr. Hatwig received his Bachelor’s degree in Pharmacy from the University of Arkansas. He further completed residencies in Hospital Pharmacy and Hospital Pharmacy Administration at the University of Wisconsin culminating in a Master’s degree in Hospital Pharmacy. Before joining Apexus, he was the Director of Ambulatory Pharmacy Services and Value Analysis Programs at Parkland Health & Hospital System in Dallas where he practiced for 13 years managing one of the nation’s largest and more progressive ambulatory pharmacy programs serving the low-income and uninsured. He was responsible for managing Parkland’s network of ambulatory pharmacies, which processed over two million prescriptions annually and operated with a drug expense budget of $65 million.

Mr. Hatwig is a member of the American Society of Health-system Pharmacists (ASHP), the Academy of Managed Care Pharmacy (AMCP) and the American Pharmacists Association (APhA). In 2009, he received ASHP’s Award of Excellence for contributions to pharmacy practice.

Mr. Hatwig is frequently consulted on how to maximize the benefits of the 340B Program. He routinely makes national and regional presentations related to the 340B drug pricing program, innovative ambulatory pharmacy services, and drug cost containment strategies.

Return to Speakers page »